Besides its involvement with investment company Genextra (InnovHeart investor since 2015), the €20M Series B round signed this week by Italian MedTech company InnovHeart included an investors union led by venture capitalist Panakes Partners, together with CDP Venture Capital Sgr – Fondo Nazionale Innovazione and Indaco Venture Partners.
The initiative will support the upcoming development phases of Saturn, the Transcatheter Mitral Valve Replacement (TMVR) medical device created by InnovHeart. Over the following months the company is to conduct a First-in-Human, trans-apical clinical check on the device, also bringing the delivery system to trans-septal completion.
INNOVHEART, THE COMPANY
WITH OFFICES IN MILAN (ITALY) AND NEWTON (MASSACHUSETTS), INNOVHEART S.R.L. DEVELOPS SYSTEMS FOR TREATING PATIENTS LIVING WITH MITRAL VALVE DISEASE. IT WAS FOUNDED IN 2015 BY GIOVANNI RIGHINI, OWNER OF OVER 30 PATENTS WITHIN THE MEDTECH FIELD.
InnovHeart was founded on Italian excellence within the engineering and medical fields. As Saturn technology creator, Giovanni Righini has over 30 years’ experience in heart valve design while cardio-surgical advisor Paolo Denti hails from the renowned school of Professor Ottavio Alfieri at Milan’s San Raffaele.
SATURN, A SOLUTION FOR MILLIONS OF PEOPLE
The innovation offered by InnovHeart can aim to represent the best-in-class Mitral Regurgitation treatment device - on a global scale. In its most severe form, the pathology affects more than 4 million people in the USA and Europe alone, 85% of whom remain uncurable by today’s technologies. Thanks to its innovative features, Saturn can significantly increase the number of treatable patients, thereby improving the life expectancy of millions of people over the years to come.